These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37783154)

  • 1. Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ.
    Zhang M; Barroso E; Ruart M; Peña L; Peyman M; Aguilar-Recarte D; Montori-Grau M; Rada P; Cugat C; Montironi C; Zarei M; Jurado-Aguilar J; Camins A; Balsinde J; Valverde ÁM; Wahli W; Palomer X; Vázquez-Carrera M
    Biomed Pharmacother; 2023 Nov; 167():115623. PubMed ID: 37783154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis.
    Li TH; Yang YY; Huang CC; Liu CW; Tsai HC; Lin MW; Tsai CY; Huang SF; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
    Clin Sci (Lond); 2019 Feb; 133(3):531-544. PubMed ID: 30602573
    [No Abstract]   [Full Text] [Related]  

  • 3. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
    Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
    Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the Role of PPARβ/δ in NAFLD.
    Chen J; Montagner A; Tan NS; Wahli W
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
    Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M
    Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
    Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.
    Zarei M; Barroso E; Palomer X; Escolà-Gil JC; Cedó L; Wahli W; Vázquez-Carrera M
    Clin Investig Arterioscler; 2019; 31(3):111-118. PubMed ID: 30987865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
    Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
    World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.
    Shan W; Palkar PS; Murray IA; McDevitt EI; Kennett MJ; Kang BH; Isom HC; Perdew GH; Gonzalez FJ; Peters JM
    Toxicol Sci; 2008 Oct; 105(2):418-28. PubMed ID: 18622026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease.
    Zarei M; Aguilar-Recarte D; Palomer X; Vázquez-Carrera M
    Metabolism; 2021 Jan; 114():154342. PubMed ID: 32810487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GQ-130, a novel analogue of thiazolidinedione, improves obesity-induced metabolic alterations in rats: Evidence for the involvement of PPARβ/δ pathway.
    Silva OA; Ribeiro-Filho HV; Avelino TM; Tittanegro TH; Figueira ACM; Rabelo LA; Pitta IDR; Lahlou S; Duarte GP
    Clin Exp Pharmacol Physiol; 2020 May; 47(5):798-808. PubMed ID: 31909493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.
    Alvarez-Guardia D; Palomer X; Coll T; Serrano L; Rodríguez-Calvo R; Davidson MM; Merlos M; El Kochairi I; Michalik L; Wahli W; Vázquez-Carrera M
    Biochim Biophys Acta; 2011 Feb; 1811(2):59-67. PubMed ID: 21070867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation.
    Barroso E; Rodríguez-Rodríguez R; Chacón MR; Maymó-Masip E; Ferrer L; Salvadó L; Salmerón E; Wabistch M; Palomer X; Vendrell J; Wahli W; Vázquez-Carrera M
    Biochim Biophys Acta; 2015 May; 1852(5):1049-58. PubMed ID: 25728706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
    Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
    Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy.
    Koga T; Yao PL; Goudarzi M; Murray IA; Balandaram G; Gonzalez FJ; Perdew GH; Fornace AJ; Peters JM
    J Biol Chem; 2016 Nov; 291(48):25255-25263. PubMed ID: 27765815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.
    Goudarzi M; Koga T; Khozoie C; Mak TD; Kang BH; Fornace AJ; Peters JM
    Toxicology; 2013 Sep; 311(3):87-98. PubMed ID: 23851158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity.
    Toral M; Gómez-Guzmán M; Jiménez R; Romero M; Zarzuelo MJ; Utrilla MP; Hermenegildo C; Cogolludo Á; Pérez-Vizcaíno F; Gálvez J; Duarte J
    J Hypertens; 2015 Sep; 33(9):1831-44. PubMed ID: 26147382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.